Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Tarsus PharmaceuticalsEli Lilly
Last price
$74.46$1,143.12
Currency
USD
USD
$3.2B$1T
-38.36
-$1.08$29.79
0.540.50
0$6.69
00.61%
Sector
HealthHealth
Employees
37050,000
Ticker
$TARS$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $TARS or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.